Pemphigus foliaceus-repeated treatment with rituximab 7 years after initial response: A case report

4Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

Abstract

Pemphigus foliaceus is an autoimmune skin disease mediated by autoantibodies directed against desmoglein-1 located in the upper epidermal layer. Rituximab, a monoclonal anit-CD20 antibody depleting b-cells, offers an effective treatment possibility for therapy-resistant pemphigus foliaceus. Here, we present the case of 55-year-old man who did not respond sufficiently to conventional treatment with prednisolone, azathioprine, and cyclophosphamide, but underwent almost complete remission after rituximab treatment. The patient relapsed 7 years later, and a repeated course of rituximab infusions led to a partial remission.

Cite

CITATION STYLE

APA

Kraft, M., & Worm, M. (2018). Pemphigus foliaceus-repeated treatment with rituximab 7 years after initial response: A case report. Frontiers in Medicine, 5(NOV). https://doi.org/10.3389/fmed.2018.00315

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free